Breaking News

PDS to Launch New Products at SOT Meeting

By Kristin Brooks | March 24, 2014

Will demonstrate Ascentos, TranSEND, and Q-Finder solutions

PDS is launching several new products at the Society of Toxicology 2014 Annual Meeting, along with a new branding campaign reflecting the company’s recent change in strategic focus. “As our new branding suggests, we have been making software that works like scientists think for more than 30 years,” said Sayed Badrawi, chief executive officer of PDS. “Our latest products are the ultimate refinement of that concept.”
PDS will demonstrate Ascentos, an integrated software suite for preclinical research, and TranSEND, a new FDA submission management solution designed to automate data translation from multiple sources into a single set of harmonized SEND files in compliance with new submission standards. The company will also introduce its Q-Finder, a bioinformatics data analysis and visualization platform.
“We expect to make a splash at SOT,” said Maro Schuster, senior vice president of business development. “We have breakthrough technology in preclinical data management, and we’re eager to show it to our clients and colleagues.” 

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research